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Preface 
 
Student’s role 
 
I was responsible for all analyses and writing up the report. My supervisors Dr Zhang and Dr 
Laing came up with the project. The aim of this project is to try to find cluster memberships 
based on clinical phenotypes in children with severe asthma and determine whether we could 
use it to predict their response to treatment. They thought that as someone who has no 
preconceived idea on asthma, I’d be ideal to do this project. The idea is for me to find 
clusters that have never been found before. To start with, I performed a preliminary 
exploratory data analysis on the clinical phenotypic data, questionnaire data and blood 
sample levels data to get better ideas on the data itself and to determine which variables I 
should use. Prof Nick de Klerk was kind enough to come on board to supervise me towards 
the middle of my project and offered a different perspective in seeing the data. After further 
consultations and more in-depth investigation on asthma clinical phenotypes, we decided to 
use multivariable linear regression to select which variables I would use for my cluster trials. 
This way I would also have a better understanding of the relationship between each covariate 
and the outcome variable – which was the response to treatment. Both univariate and 
multivariable linear regressions were conducted. I started the selection of covariates process 
univariately and then all covariates that were significant at 20% level were considered as 
potential covariates for the inclusion into the multivariable model. The variables used in the 
final multivariable model were deemed the best fitted and then used in the cluster analysis to 
build the cluster memberships. The final cluster memberships used in this project were 
constructed after several trials and tests, both within the clusters themselves and between the 
clusters and the outcome of interest. The clusters were also tested against genotypes of 
several important asthma candidate genes and virus data to test for differing susceptibility to 
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viral infection. Lastly, I performed multivariable Poisson regression on the available hospital 
presentation data to see if the recurrence of hospitalization varied between phenotypes and 
was influenced by any particular respiratory risk factors. All the data used in this project was 
derived from results from MAVRIC study. My supervisors and I intend to submit aspects of 
this report for publication.  
 
Reflections on learning 
 
Clinically, undertaking this project was a very challenging task for me. I had no clinical 
background whatsoever, especially in paediatric asthma. I had to learn, and am still learning, 
a lot about asthma and its impact on children. I also had to learn about a lot of allergy, 
genetics, viruses, blood samples and plasma levels and all the accompanying biomedical 
terminology to get a well-rounded idea about paediatric asthma and what MAVRIC study are 
all about.  
 
Statistically, this project also imposed lots of challenges. Cluster analysis is a new concept 
for me and was not covered in BCA units. One of my statistical supervisors, Dr Zhang, came 
up with this idea. He advised me to use the k-means clustering method for the purpose of my 
analysis. The reasoning was because k-means method is quite simple to implement and has 
been successfully utilized in medical and applied statistics (Haldar et al., 2008). As with the 
clinical subject, I had to learn and familiarize myself with the clustering method. This process 
took months, especially when I started conducting my cluster trials. At the end, I ended up 
combining multivariable regression and cluster analysis in the variable selection process and 
to have better understanding of the dynamics of the relationship between the covariates and 
the outcome of interest both individually and combined. Prof De Klerk further suggested for 
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me to investigate the hospitalization recurrence after the participants were recruited in the 
study. As the hospital visits data were count data, I used negative binomial regression model 
for the analysis. In doing the overall statistical analysis, I drew a lot from skills and 
knowledge I gained from BCA units in particular Linear Modelling (LMR) and Categorical 
Data Analysis (CDA).  
 
Another major thing I learnt along the way is about the data itself. MAVRIC is a large study 
that has been going on for more than a decade. The original questionnaire that they used has 
evolved accordingly to reflect this. As a result, familiarization with the dataset has proven to 
be a difficult task. There are easily more than a thousand variables in the overall dataset. The 
dataset is constructed from various individual databases: questionnaire, acute data, short-term 
follow up data, long term follow up data, skin prick test, FBC, lung function test, levels, PNA 
(virus), PCAAS and genotype. Although I would not be using or needing all of these data I 
was still required to be familiar with them well enough to choose the most appropriate 
variables and to interpret their values and effects correctly. The whole process took me just 
over 1.5 years. 
 
Teamwork 
 
This project involved close collaborations with Dr Brad Zhang, Prof Nick de Klerk, Dr Ingrid 
Laing, who are my statistical and clinical supervisor respectively. Dr Zhang and I had many 
discussions and conducted many clustering trials together throughout the course of the 
project. Prof Nick de Klerk provided an additional and invaluable support for the statistical 
challenges I faced, in the discussion of the analysis and the interpretation of the results – 
especially when the clustering analysis alone did not yield sufficient information to base our 
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conclusions on. We met frequently to discuss about what other options we could do with the 
data we had. He suggested the multivariable linear regression and negative binomial 
regressions on top of the cluster analysis to answer some pertinent research questions. Dr 
Laing and I mostly discussed about the clinical side of the project. She helped me to view the 
results from a wider context and how it all fits the bigger picture. She helped me to apply 
statistics to a clinical setting and for it to be understood by a wider audience. Prof Peter Le 
Souef, the head of School of Paediatrics and Child Health, was there to oversee the whole 
process. He was always supportive when I expressed the difficulty I had with the data at 
times at the team’s weekly lab meeting.  I also closely collaborated with Dr Joelene 
Bizzintino, who is in charge of the overall MAVRIC database. Her assistance was invaluable.  
 
Ethical considerations 
 
MAVRIC study obtained consent form from study participants and ethics approval (1761/EP) 
for recruitment and subsequent follow-ups from the Ethics Committee at Princess Margaret 
Hospital (Perth, WA, Australia). 
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Project Summary 
 
 
Project title 
Clinical phenotypes associated with impaired response to treatment in children with acute 
asthma 
 
Location and dates 
This project was completed at the School of Paediatrics and Child Health at the University of 
Western Australia between January 2014 and September 2015. 
 
Context 
This project is part of a larger study titled “Mechanisms of Acute Viral Respiratory Infection 
in Children (MAVRIC)”. It is a prospective study of the role of viruses and immunogenetic 
risk profiles for viral infections. My project's aim is to identify distinct phenotypic groups 
using cluster analysis and to explore the association between those identified clusters both 
with asthma candidate genes and with a susceptibility to human rhinovirus. The acute asthma 
cohort from the MAVRIC study provides a unique opportunity to investigate this research 
question.  
 
Student contribution 
• Investigation of asthma clinical phenotypes and potential risk factors in children 
• Exploratory data analysis and preparation of data for analysis 
• Fitting of linear regression models to determine the relationships between asthma 
clinical phenotypes and potential risk factors in children 
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• The construction of cluster memberships to see if there were any groups emerging 
within these clinical phenotypes and potential risk factors 
• Conducting the cluster analysis to see if the cluster memberships were associated with 
the response to treatment, and a selection of asthma-related genotypes.  
• Fitting of negative binomial regression models to determine the association between 
cluster memberships, asthma clinical phenotypes and potential risk factors, with the 
recurrence of hospital presentations after the children were recruited into the 
MAVRIC study. 
 
Statistical issues 
• Evolving questionnaire 
MAVRIC study began more than 10 years and since then the questionnaire used has 
evolved. This has imposed constant data cleaning and analysis challenges. Many 
questions have become obsolete and were duly replaced. This in turn has caused 
responses to these questions becoming patchy.   
• Missing data   
A direct effect from an evolving questionnaire has been missing data. There had been 
questions that participants were asked differently depending when they were 
recruited. This has led to a considerable amount of missing data.  
Another issue was the fact that not all children were tested for respiratory viruses and 
the asthma-related genes were only typed for small number of cases. This caused a 
major missing data issue.    
• Multiple handling of data entry 
Further inconsistencies in the data can be attributed to the data entry process, which 
was carried out by different people. Differing interpretations have produced multiple 
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problems. For example, answers to the question “How many time did your child 
experience asthma exacerbation in the past 3 months?” vary from “twice” to “2”, 
“two”, “two times” and “?”. This inconsistency has made data cleaning a time-
consuming process.  
• Lack of data dictionary at the beginning 
A considerable challenge was the absence of a data dictionary for the project that 
would have provided a description of variables and the theoretical foundations for the 
questions. My clinical supervisor's help in interpreting the project was invaluable in 
slowly coming to grips with the detailed nature of the study. 
• Selection of variables for data analysis  
MAVRIC has vast amount of variables in the dataset. It took some familiarization 
with the study itself, the topics of paediatric asthma, immunology, and genetics, to try 
narrowing it down to a more asthma-specific focus, so that appropriate potential 
variables could be considered for analysis purposes.  
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Glossary 
 
Atopy A predisposition towards developing certain allergic hypersensitivity. 
Eosinophils White blood cells that control mechanisms associated with allergy and 
asthma. Increased level of eosinophils in peripheral blood and in 
airway secretions are characteristic feature of asthma. 
Neutrophils A type of white blood cells that formed an essential part of the innate 
immune system. Increased level of neutrophils in induced sputum is 
usually a sign of asthma.  
Salbutamol A short-acting β2-agonist used for the relief of bronchospasm in 
conditions such as asthma and chronic obstructive pulmonary disease. 
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List of Abbreviation   
 
Adv Adenovirus 
ED Emergency Department 
HRV Human Rhinovirus 
HRV-C Human Rhinovirus (strain) C 
IgE Immunoglobulin-E 
InfV Influenzae (strain) A 
Myco Mycoplasma Pneumoniae Virus 
PIV Parainfluenzae Virus 
PNA Peptide Nucleid Acid 
RSV Respiratory Syncytial Virus 
SPT Skin Prick Test 
VRI Viral respiratory infection 
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Project report 
 
Clinical phenotypes of acute asthma associated with impaired response to treatment in 
children with acute asthma  
 
Introduction 
 
Asthma comprises inflammation of the airways, characterised by reversible airways 
obstruction, airway hyper-responsiveness (AHR) and bronchial spasm (Dougherty & Fahy, 
2009). Asthma, particularly childhood asthma, is a National Health Priority costing Australia 
>$606 million annually. First symptoms of asthma usually occur during the first few years of 
childhood. Of those, a large proportion of children become symptom free by the time they 
reach school age and the rest continue to develop persistent asthma throughout childhood 
(Martinez & Vercelli, 2013).  
 
The aetiology of asthma is complex as it is multifactorial, with contributions from both 
genetic heritability and environmental stimuli. The interaction between genetics and 
environment makes asthma a heterogeneous syndrome with overlapping individual 
phenotypes (Borish & Jeffrey, 2008). This heterogeneity of asthma makes the task of treating 
asthma quite problematic, as the specific mechanism of asthma that leads to the airway 
dysfunction has still not been properly identified (Drazen, 2012). As a result, the response to 
asthma medication varies considerably from patient to patient depending on the level of 
sensitivity of the different asthma phenotypes (Borish & Jeffrey, 2008).  
 
The causes of acute asthma exacerbations are numerous. Environmental stimulus such as 
virus and allergens can cause inflammation of airways with resultant loss of control of 
  
16 
 
asthma, which results in an exacerbation (Lenney, 2009; Martin et al., 2006).  Genetic 
susceptibility can also make children more prone to developing asthma (Taussig, 2002). The 
likelihood of these precipitants to cause exacerbation of this heterogeneous disease varies 
among children depending on their asthma phenotype (Dougherty & Fahy, 2009).  
 
Viral respiratory tract infections, in particular those caused by human rhinovirus (HRV), are 
believed to be the most common cause of acute asthma exacerbations (Bizzintino et al., 2011; 
Jackson et al., 2010). It is very likely because HRVs can affect the lower airway and are very 
common infection in infant and young children (Cox & Le Souef, 2014; Papadopoulos et al., 
2000). Other viruses such as respiratory syncytial virus (RSV) can also cause acute 
exacerbations, with a higher prevalence found on children with a family history of asthma 
(Bizzintino et al., 2011; Papadopoulos et al., 2011).  
 
Genetic predisposition plays an important role in the development of childhood asthma 
(Hodges, 1996; Sibbald et al., 1980). Twin studies from 1970s to 1990s found evidence of 
strong genetic component in the factors underlying allergic and Immunoglobulin-E-(IgE)-
mediated disease such as asthma (Edfors-Lubs, 1971; Duffy et al., 1990). This leads to a 
greater co-existence of the disease in monozygotic compared to dizygotic twins. Tucson’s 
1989 longitudinal respiratory study of in children found that those with a family history of 
asthma were more likely to develop persistent asthma compared to those without a family 
history of asthma (Taussig, 2002). It is thought that these genetic predispositions cause 
children to develop hypersensitivity to specific allergens that make them susceptible to 
developing allergy and IgE-mediated disease. 
 
  
17 
 
Martin et al. (2006) found that CD14 and CC16 played an important role in the immune 
system and airway inflammation. The increased levels of both protein levels illustrated their 
role during an acute episode. Their study also found that children with CD14 C-159T and 
CC16 A38G genotypes are more likely to suffer a more severe level of acute asthma 
exacerbation compared to those with other genotypes.  
 
Immunoglobulin E (IgE) is a type of antibody known to trigger inflammation and allergic 
reactions (Platts-Mills, 2001). Total serum IgE and allergen-specific IgE are two 
measurements that are commonly used to establish a child’s allergic status. A high level of 
total IgE concentrations usually is sufficient to establish a presence of allergy; nonetheless, a 
low level of total IgE does not preclude the presence of allergen-specific IgE (Sinclair & 
Peters, 2004). Thus, the allergen-specific IgE is often requested to accompany total IgE as 
well. Furthermore, allergen-specific IgE measurement also provides additional information 
on the level of allergy to a specific allergen or group of allergens that is not available from 
total IgE.  
 
Another most widely used method to determine allergy and atopy status in children is via 
skin-prick testing (SPT). SPT results are commonly used in conjunction with total serum IgE 
and allergen-specific IgE as together they provide better chance of allergy detection (Sinclair 
& Peters, 2004). Total serum IgE, allergen-specific IgE, SPT results and atopy status are 
among the most common phenotypes used as markers in asthma studies (Martinez & 
Vercelli, 2013). 
 
Few studies have tried to examine the different clinical phenotypes of asthma in both adults 
and children (Haldar et al., 2008; Kelley et al., 2005; Moore et al., 2009). Haldar et al. (2008) 
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and Moore et al. (2009) both applied the principle of cluster analysis to identify distinct 
asthma phenotypic groups in adults. Kelley et al. (2005) used multivariable regression to 
determine if risk factors and measures of severity varied between children with different 
asthma phenotypes.  
 
To date, no studies had tried to clarify asthma phenotype groups in children with severe 
asthma. The Mechanisms of Acute Viral Respiratory Illness in Children (MAVRIC) study 
provides a unique opportunity to investigate this research question using the combination of 
the use of cluster analysis and multivariable regression techniques.  
 
This project aims to predict the treatment response by identifying a specific group of children 
with acute wheezing and asthma who do not respond the treatment well and are likely to 
relapse and re-present to hospital. The recurrence of hospital presentations was further 
examined to see whether it is associated with specific asthma phenotypes and potential risk 
factors.  
 
Methods 
Study participants 
Study participants were children recruited from the Mechanisms of Acute Viral Respiratory 
Infection in Children (MAVRIC) Study that began in 2001. The MAVRIC study recruited 
children with acute viral respiratory infection that led to hospital admission, between the ages 
0 to 18, with and without a cold at the time of recruitment from the Emergency Department 
(ED) at Princess Margaret Hospital for Children (PMH). As MAVRIC is an ongoing study 
and continues to recruit participants, a cut-off was made at case number 702 for the purpose 
of analysis (n = 702).   
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Potential covariates  
There were six types of data used in this study:  
1. The questionnaire data. This consists of the child’s history of allergy and asthma 
exacerbation, hospital presentation, family background and history of allergy and 
asthma.  
2. Skin prick test data. This consists of the results from skin prick test from 11 allergens. 
The complete list of the 11 allergens is provided in Table 1.  
3. Full blood count data. This consists of peripheral blood differential count during acute 
asthma exacerbation.  
4. Serum levels for total IgE and allergen-specific IgEs during acute asthma 
exacerbation.  
5. PNA (Peptide Nucleid Acid) data. This consists of information from virus typing 
results.  
6. Genotypes data. This consists of information from genotyping results.   
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Table 1: List of 11 allergens used in skin prick test 
Allergens 
1. Mixed ryegrass 
2. Alternaria tenuis (fungus) 
3. Dermatophagoides farinae (American house dust mite) 
4. Whole cow’s milk 
5. Dermatiphagoides pteronyssinus (European house dust mite) 
6. Aspergillus fumigatus (mould or filamentous fungi) 
7. Egg white 
8. Mixed grasses 
9. Cat pelt 
10. Dog hair and dander 
11. Cockroach – American and German 
 
One of the limitations of the study was that not all children got tested for viruses and not all 
the genes were typed, which resulted in a significant number of missing values. So for the 
purpose of the statistical analysis, only variables collected for 500 or more children were 
selected. For the gene-specific variables, only those that were genotyped in more than 180 
children were selected. The lists of potential variables are listed below:  
 
Table 2: List of potential continuous variables 
Continuous variables 
1. Age 
2. Neutrophils level 
3. Eosinophils level 
4. Severity of acute asthma exacerbation 
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Table 3: List of potential categorical variables 
Categorical variables 
1. Gender 
2. Viral infection to respiratory-related virus present during acute exacerbation 
3. Human rhinovirus (HRV) present during acute exacerbation   
4. Human rhinovirus C (HRV-C) present during acute exacerbation 
5. Adenovirus (AdV) present during acute exacerbation 
6. Respiratory syncytial virus (RSV) present during acute exacerbation 
7. Influenzae A (InfV) virus present during acute exacerbation 
8. Parainfluenzae virus (PIV) type 1, 2 or 3 present during acute exacerbation 
9. Mycoplasma pneumoniae (Myco) virus present during acute exacerbation 
10. Aero-allergy status (encompasses both aero-atopy and allergy) 
11. Child’s asthma diagnosis status 
12. Mother past smoking status 
13. Mother current smoking status 
14. Household member’s past smoking status 
15. Household member’s current smoking status 
16. Child usually have a cough 
17. Child ever wheezed 
18. Family history of asthma 
19. Previous hospitalization due to asthma 
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Table 4: List of potential gene-specific variables 
CD14_159CT GSTP1114 TLR3_6300CT TLR_746AG 
CC16_38AG IL8_781CT TLR3_8441AT X5LO_1708GA 
CysLT1_927TC IL8_251AT TLR7_17961AT ST2_26999AG 
GSTM1 IL13_1112CT TLR7_4452CT LTC4S_444AC 
GSTP1105 IL13_130GA TLR8_558CT LTC4S_1072GA 
 
Outcome variables 
Short-term outcome 
- Length of hospitalization (hours).  
This represents how long each patient was kept in the hospital starting from when 
they presented themselves to ED due to acute exacerbation and finishing when they 
were deemed fit enough to be discharged.  
- Dose of β2-agonist administered within the first 24 hours of asthma exacerbation.  
This represents the emitted dose of inhaled β2-agonist needed by patients to relieve 
their exacerbation within 24 hours. One dose equals to six puffs whereby each puff 
contains 100mcg of salbutamol (β2-agonist).  
 
Long-term outcome (after recruitment) 
There were two aspects of long-term outcome measured in this study: (1) the total number of 
inpatient admissions; and (2) the total number of ED visits resulting from respiratory illness, 
that occurred after the children were recruited into the MAVRIC study. The inpatient 
admissions and ED visits were chosen because they were the most relevant measures of acute 
asthma exacerbations.  
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Data preparation 
1. Binary coding was done for most of the categorical variables.  
2. A preliminary exploratory data analysis was performed on both continuous and 
categorical variables, including the short-term outcome variables. The results indicated 
that age, neutrophils level, eosinophils level, length of hospitalization and β2-agonist dose 
were skewed. Hence they were all log-transformed. Natural log (ln) was used for the 
transformation. A more detailed result from the preliminary exploratory data analysis is 
provided in Appendix 1. 
3. The severity score. The score represents the severity of acute exacerbation. Severity 
scoring results were standardized using z-scores because the scoring mechanism was 
different for children under 2 and those 2 and over. Standardizing the results allowed the 
scores to be amalgamated and thus enable the level of severity to be compared across 
different ages. For children 2 and over, the score was determined by MAVRIC 
investigator using a modified National Institutes of Health Scores (Reddel et al., 2009). It 
applied clinical parameters that were corrected to baseline (Bizzintino et al., 2011). The 
scoring had three categories:  
o Mild: score of 0-2 
o Moderate: score of 3-6 
o Severe: score of 7-10 
For children under 2, different clinical scoring system adapted from Bentur et al. (1992) 
was applied. There were four variables the children were tested on:  heart rate, 
respiratory rate, the degree of accessory muscle use and wheezing. The sum of the 
individual score for these four variables made up the total clinical score for each child.  
More details of the clinical scoring system are provided in Table 5.  
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Table 5. The clinical scoring system for acute asthma exacerbation for children < 2  
 
4. Aero-atopy status: This indicates whether someone is atopic or not, based on their skin 
prick test result; and allergen-specific IgE levels (house dust mites and cats) during an 
acute exacerbation.  As the focus is on airflow obstruction and airway inflammation, only 
skin prick test results from inhaled allergens were included here. 
 
Statistical analysis 
There were three components of statistical methodology used in this study: Multivariable 
linear regression analysis, cluster analysis and multivariable Poisson/negative binomial 
regression analysis. All analysis was conducted in both Stata version 14 and SPSS version 
22. 
 
1. Multivariable linear regression  
Multivariable linear regression was conducted to determine whether response to 
treatment varied between phenotypes and whether potential risk factors played a part 
in it. The response to treatment was measured by the length of hospitalization and the 
Score Heart 
Rate 
Respiratory 
Rate 
Wheezing Accessory Muscle 
Use 
0 ≤120 ≤30 None and well None 
1 121 – 140 31 - 45 End-expiratory only Mild 
2 141 – 160 
 
46 - 60 Entire expiration + 
inspiration with 
stethoscope only 
Moderate (including 
tracheosternal) 
3 >160  >60 Loud wheezing audible 
without stethoscope (or 
silent chest in the presence 
of tachypnea) 
Severe with nasal 
flare 
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dose of β2-agonist required within 24 hours of acute exacerbation. This method was 
chosen mainly because (1) the outcome (the response to treatment) was a continuous 
variable; (2) the covariates (the phenotypes and the potential risk factors) were a 
mixture of continuous and categorical variables; (3) there were potential confounders 
that need to be taken into account when ascertaining the effect of the covariates of 
interest. Basically this study would like to create a model that explains the variation in 
the response to treatment conditional on the values of phenotypes and risk factors.  
 
Multivariable linear regression was also used to determine if genotypes played a role 
in how a child responds to a treatment. Selection of variables for the purpose of 
multivariable linear regressions analysis was based on the univariate linear regression 
analysis results. Univariate linear regression was conducted for each of the predictor 
variable against each of the outcome variable. All variables that were significant at 
the 20 percent level were deemed as candidates for inclusion in the multivariable 
analysis. However, for the alpha level was set at 0.05 for the final multivariable 
model. Model checking for the final multivariable model is provided in the Appendix 
2.  
 
2. Cluster analysis  
Cluster analysis was conducted as an exploratory investigation of the collected 
questionnaire data, skin prick test data, full blood count data, peptide nucleic acid data 
and levels data to see if there was any groups emerging within these clinical 
phenotypes and potential risk factors; and how these clusters associated with the 
length of hospitalization, dose of β2-agonist required within 24 hours of exacerbation, 
and asthma-related genotypes such as CD14 159CT and CC16 A38G that have been 
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shown to react differently depending on the severity level of acute asthma in children 
(Martin et al., 2006). Linear regression was used to identify variables to be included 
in the cluster analysis with variables that were significant at the 20 percent level were 
deemed as candidates for inclusion. 
Kaufman and Rousseeuw (1990) defined cluster analysis as “the art of finding groups 
in data”. There are several methods of cluster analysis, whereby the difference 
between them mostly lie in how they measure the “distance” which is the similarity or 
the dissimilarity between observations (Everitt et al., 2011).   
 
A k-means cluster analysis method was chosen over another method because it best 
suited MAVRIC’s medium-sized data, and because it does not require complex 
calculation of the “distance”, as it uses Euclidean distance in its calculation by 
default. K-means clustering works by simply partitioning the available observations 
(n) into k clusters and then grouping them into a cluster with the nearest means. The 
only drawback with k-means method is that the number of clusters or “k” must be 
decided prior to the analysis. Mirroring the approach taken by Haldar et al. (2008) on 
their cluster analysis study, after the emergence of clusters, the between-clusters 
comparison of covariates of interest was performed using one-way analysis of 
variance (ANOVA) for continuous variables and a chi-square test (χ2) for categorical 
variables. Univariate ANOVA with the cluster membership as a covariate was further 
performed to verify the significance of the cluster as a predictor for any observed 
differences in the outcome. 
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3. Multivariable Poisson/negative binomial regressions 
For the last part of the analysis, the study wished to explore the effects of the 
enrolment admission characteristics on the rate of further ED visits and hospital 
admissions. Poisson and Negative Binomial regressions were chosen because the rate 
of occurrence of ED visits and inpatient admissions were count variables.  
 
Poisson regressions were first applied to the data and were then compared with 
negative binomial models to look for over-dispersion or variability in the 
admission/visit rates that was greater than would be expected under a Poisson 
distribution. Negative binomial regression fit the model in a manner similar to 
Poisson regression except it allows extra variation in the count data than Poisson 
which would accommodate any potential case of over-dispersion. The result of the 
comparison between the two models indicated significant over-dispersion and so 
negative binomial regression was conducted throughout to determine whether 
recurrence of inpatient and ED visits varied between phenotypes and whether 
potential risk factors played a part in it.  
 
The hospital presentation data collected from all public hospital in WA combined 
with MAVRIC data was used for this purpose. Cluster memberships resulting from 
the cluster analysis were also included as explanatory variables to determine whether 
the amount of inpatient and ED visits varied between clusters. 
 
The selection of variables for the purpose of multivariable negative binomial 
regressions was based on the univariate negative binomial regression analysis results. 
Univariate analysis was conducted for each of the predictor variable against each of 
  
28 
 
the outcome variable. All variables that were significant at the 20 percent level were 
deemed as candidates for inclusion in the multivariable analysis.  Variables were 
included in final models if the p-value for removal was less than or equal to 0.05 or 
they were probable or known confounders. 
 
The potential covariates remained the same as the ones used for the multivariable 
linear regressions analysis with the addition of cluster membership information. 
However the outcome of interest was now set to the number of inpatient and ED visits 
after the recruitment to MAVRIC study. Length of hospitalization and dose of β2-
agonist required within first 24 hours of acute asthma exacerbation were included as 
potential determinants in addition to the aforementioned phenotypes. The analysis 
was adjusted for age at recruitment. The duration of time at risk was counted from the 
date of recruitment into the MAVRIC study until the date of final observation of the 
WA hospital admission data (which was the same for everybody - March 31, 2014).  
 
Fractional polynomial models were applied to the continuous variable so as to find the 
best fit for the covariates of interest when they were entered to the linear predictor in 
the negative binomial regression model (Sauerbrei et al, 2007). Only children aged 12 
months and older were included in the analysis for two reasons: (1) For most of these 
infants, the recorded trip to hospital was their first one; (2) Most of these infants were 
not given the reliever that was given to the older ones – i.e. they were not given 
salbutamol (β2-agonist). Therefore the existence of their data had the potential to 
skew the covariates distribution for the rest of the study cohort and thus was excluded. 
Model checking for the final multivariable model (including test for over-dispersion) 
is provided in the Appendix 2.  
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Results 
 
Summary of study participants’ characteristics 
Overall there were 700 cases observed in this study, however due to missing observations, 
cases that were not tested for virus and lost hospital notes, the majority of variables had less 
than 700 cases in them.  
The average age was 5 years old.  The majority of the cases were male (60%), asthmatic 
(65%), and were atopic and/or allergic (62%). 81% of them were positive for viral infection 
to respiratory-related virus, and of those tested positive, 69% of them were positive for 
human-rhinovirus. 86% of the cases had bouts of wheezing in the past 12 months. 53% had 
previously been hospitalized due to asthma and 82% had family history of asthma. More 
details on the study participants’ characteristics are provided in Table 6 and Table 7.  
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Table 6. Summary of categorical data 
Variable [n (%)] n   
Gender  694 Male [418 
(60)] 
Female [276 
(40)] 
Positive for respiratory-related virus 628 Yes [509 (81)] No [119 (19)] 
HRV positive  607 Yes [421 (69)] No [186 (31)] 
HRV-C positive  604 Yes [235 (39)] No [369 (61)] 
Adenovirus  701 Yes [10 (1)] No [691 (99)] 
Respiratory virus  502 Yes [74 (15)]  No [428 (85)] 
Influenzae A  500 Yes [5 (1)] No [495 (99)] 
Mycoplasma pneumoniae 616 Yes [3 (1)] No [613 (99)] 
Aero-atopy and allergy status 701 Yes  [437 (62)] No [264 (38)] 
Asthma diagnosis status 688 Yes [444 (65)] No [244 (35)] 
Mother’s past smoking status 668  Yes [248 (37)] No [420 (63)] 
Mother’s current smoking status 668 Yes [118 (18)] No [550 (82)] 
Household member’s past smoking status 542 Yes [236 (44)] No [306 (56)] 
Household member’s current smoking 
status 
641 Yes [168 (26)] No [473 (74)] 
Presence of cough 664 Yes [255 (38)] No [409 (62)] 
History of wheezing 662 Yes [571 (86)] No [91 (14)] 
Family history of asthma 666 Yes [546 (82)] No [120 (18)] 
Previous hospitalization due to asthma 664 Yes [349 (53)] No [315 (47)] 
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Table 7. Summary of continuous data 
Variable [median (IQR)] n  
Age, years  700 4 (2 to 7) 
Neutrophil level, x 109 g/L  512 8.2 (5.17 to 10.9) 
Eosinophil level, x 109 g/L  512 0.05 (0 to 0.24) 
Length of hospitalization, hours  680 28 (16.5 to 52) 
Inhaled dose of β2-agonist in 24 hours, mcg  541 13 (9 to 18) 
Severity of acute exacerbation, z-score  613 -0.11 (-0.53 to 0.74) 
 
Short-term outcomes 
Both univariate and multivariable linear regression analysis were used in this study. 
Univariate linear regression analysis was conducted to determine the relationship of each 
potential covariate with each of the outcome variable. Any result from univariate analysis 
that was significant at 20% level was included in the multivariable analysis.   
 
Length of hospitalization (hours) 
Age (p = 0.160), female (p = 0.002), positive for RSV, Adv and PIV (p = 0.006, 0.004 and 
0.035 respectively), mother ever smoke (p = 0.003), mother smoking now (p < 0.001), 
household member used to smoke (p = 0.05), mother smoking now (p = 0.002), coughing (p 
= 0.036), previous hospitalization due to asthma (p < 0.001), asthmatic (p = 0.005) and the 
severity of acute exacerbation (p < 0.001) were significant in influencing the patients’ length 
of hospitalization.  
 
Female, virus infection by respiratory-related virus, maternal current smoking status, 
household-member’s smoking past, previous hospitalization due to asthma and the severity of 
acute exacerbation were found to be significant in predicting patients’ length of 
hospitalization.  
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Dose of  β2-agonist within the first 24 hours of acute asthma exacerbation 
Age (p < 0.001), neutrophil level (p = 0.003), positive for respiratory-related virus (p = 0.04), 
positive for HRV (p = 0.008), positive for HRV-C (p = 0.189), positive for RSV (p = 0.003), 
positive for aero-atopy and allergy (p < 0.001), mother ever smoked (p = 0.041), mothers 
smoking now (p = 0.093), wheezing (p = 0.001), previous hospitalization due to asthma (p < 
0.001), asthmatic (p < 0.001), family history of asthma (p = 0.148), and the severity of acute 
exacerbation (p < 0.001) were found to be significant in determining the patients’ dose of β2-
agonist required to relieve their acute exacerbation.  
 
Other variables did invariably inject some influence to the length of hospitalization and the 
reliever dose, however, of a much lesser importance. The detailed results of the univariate 
regression analysis are provided in Table 8 and 9.   
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Table 8. Univariate regression analysis result for length of hospitalisation (hours) 
Variable                   β     p     95% CI 
Age (ln), years -0.050  0.160 -0.119 0.020 
Neutrophil level (ln), x 109 g/L -0.015  0.830 -0.150 0.121 
Eosinophil level (ln), x 109 g/L 0.037  0.328 -0.038 0.113 
Gender (Female) 0.219  0.002 0.082 0.357 
Positive for respiratory-related virus 0.039  0.683 -0.147 0.224 
Positive for HRV 0.029  0.716 -0.130 0.188 
Positive for HRV-C -0.044 0.566 -0.194 0.106 
Positive for AdV -0.783  0.006 -1.344 -0.221 
Positive for RSV 0.326  0.004 0.104 0.548 
Positive for InfV -0.164  0.689 -0.965 0.640 
Positive for PIV -0.518  0.035 -0.999 -0.037 
Positive for Myco -0.520  0.327 -1.562 0.521 
Positive for aero-atopy and allergy  -0.043  0.545 -0.184 0.097 
Mother ever smoked 0.220  0.003 0.077 0.362 
Mother smoking now 0.385  <0.001 0.206 0.565 
Household member ever smoked 0.158  0.050 0.000 0.317 
Household member smoking now 0.256  0.002 0.097 0.415 
Coughing -0.153  0.036 -0.296 -0.010 
Wheezing -0.106  0.302 -0.306 0.095 
Previous hospitalization due to asthma 0.248  <0.001 0.110 0.386 
Asthmatic 0.201  0.005 0.060 0.342 
Family history of asthma -0.031  0.739 -0.212 0.150 
Severity of acute exacerbation 0.141  <0.001 0.072 0.210 
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Table 9. Univariate regression analysis result for β2-agonist dose (600 mcg of 
salbutamol*) consumed in 24 hours  
Variable                   β     p     95% CI 
Age (ln), years 0.196  <0.001 0.108 0.284 
Neutrophil level (ln), x 109 g/L 0.199  0.003 0.070 0.329 
Eosinophil level (ln), x 109 g/L 0.033  0.345 -0.036 0.102 
Gender (Female) -0.081  0.205 -0.207 0.045 
Positive for respiratory-related virus 0.179  0.040 0.009 0.349 
Positive for HRV 0.209  0.008 0.055 0.364 
Positive for HRV-C 0.094  0.189 -0.047 0.235 
Positive for AdV -0.260  0.346 -0.803 0.282 
Positive for RSV -0.371  0.003 -0.616 -0.126 
Positive for InfV -0.268  0.483 -1.020 0.483 
Positive for PIV 0.170  0.586 -0.444 0.784 
Positive for Myco 0.021  0.977 -1.421 1.464 
Positive for aero-atopy and allergy 0.245 <0.001 0.114 0.376 
Mother ever smoked 0.137  0.041 0.006 0.269 
Mother smoking now 0.142  0.093 -0.024 0.307 
Household member ever smoked 0.011  0.895 -0.149 0.171 
Household member smoking now 0.039  0.606 -0.110 0.189 
Coughing 0.033  0.620 -0.097 0.162 
Wheezing 0.372  0.001 0.162 0.583 
Previous hospitalization due to asthma 0.229 <0.001 0.102 0.356 
Asthmatic 0.310  <0.001 0.177 0.442 
Family history of asthma 0.129  0.148 -0.046 0.303 
Severity of acute exacerbation 0.179  <0.001 0.115 0.243 
*1 dose equals to 6 puffs of β2-agonist, whereby each puff contains 100 mcg of salbutamol. Hence 1 
dose = 600 mcg of salbutamol. 
 
 
 
 
  
35 
 
Viral infection to respiratory-related virus, aero-atopy and allergy status, asthma diagnosis 
status and child’s severity score were significant in predicting the amount of inhaled β2-
agonist required to relieve acute exacerbation. The significant level for status of viral 
infection was actually higher than 0.05, however, it had been included in the final model 
because viral infection is deemed clinically important and might play a vital part in how a 
child responds to acute exacerbation. Complete results of multivariable analysis are provided 
in Table 10 and 11.  
 
Table 10. Multivariable linear regression analysis result for the length of hospitalisation 
(hours) (n = 426) 
Length of hospitalisation β  p 95% CI 
Gender (Female) 0.173  0.036 0.011 0.334 
Positive for RSV 0.453  <0.001 0.226 0.681 
Mother smoking now 0.286  0.001 0.151 0.560 
Previous hospitalisation due to asthma 0.286  0.001 0.121 0.451 
Severity of acute exacerbation 0.150  <0.001 0.069 0.231 
 
Table 11. Multivariable linear regression analysis result for β2-agonist dose (600 mcg of 
salbutamol) within 24 hours (n = 428) 
β2-agonist dose consumed within 24 
hours 
β  p 95% CI 
Positive for any respiratory virus 0.159  0.067+ -0.011 0.329 
Positive for aero-atopy and allergy 0.159  0.042 0.006 0.312 
Asthmatic 0.310  <0.001 0.129 0.438 
Severity of acute exacerbation 0.186  <0.001 0.116 0.255 
+Significance level > 0.05 but has been included as it is deemed as clinically important. 
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The multivariable linear regression results suggested that those who were female, positive for 
RSV, smoking mother, been hospitalized due to asthma and had more severe exacerbation 
had on average between 0.15 to 0.45 more hours in hospital than their counterpart. Further, 
those who were positive for any respiratory virus, asthmatic, were aero-atopic/allergic and 
suffered a more severe exacerbation required on average 0.16 to 0.31 higher dose of β2-
agonist within 24 hours to relieve their exacerbation compared to the rest.  
 
These final multivariable models were then fitted to determine if cases with specific genotype 
took longer in hospital and required higher dose of β2-agonist in a space of 24 hours. Out of 
20 genotypes tested, only one gene – GSTP1105 – that marginally reached 0.05 significance 
level (p = 0.062), in predicting the length of hospitalization. None of them was significant in 
predicting the dose of salbutamol consumed within 24 hours. However, this may be due to 
the small number of cases that got genotyped.  
 
Clustering of admission characteristics 
The results from univariate linear regression analyses were employed to select variables for 
the purpose of cluster analysis. The variables that were significant at the 20 percent level 
were deemed as potential candidates for inclusion in the cluster analysis. These variables are 
listed in Table 12 below. 
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Table 12: List of candidate variables for cluster analysis purpose 
Candidate variables 
1. Age 
2. Gender 
3. Neutrophil level 
4. Viral infection to respiratory-related virus present during acute exacerbation 
5. Human rhinovirus (HRV) present during acute exacerbation   
6. Human rhinovirus C (HRV-C) present during acute exacerbation 
7. Adenovirus (AdV) present during acute exacerbation 
8. Respiratory syncytial virus (RSV) present during acute exacerbation 
9. Parainfluenzae virus (PIV) type 1, 2 or 3 present during acute exacerbation 
10. Aero-allergy status (encompasses both aero-atopy and allergy) 
11. Child’s asthma diagnosis status 
12. Mother past smoking status 
13. Mother current smoking status 
14. Household member’s past smoking status 
15. Household member’s current smoking status 
16. Child usually have a cough 
17. Child ever wheezed 
18. Family history of asthma 
19. Previous hospitalization due to asthma 
20. Severity of acute asthma exacerbation 
 
Based on MAVRIC’s moderate size data, it was decided that k = 2 and 3 were good number 
of clusters to try on. One-way ANOVA and Chi-square test were conducted to see if the 
measures of covariates varied between phenotypes. One-way ANOVA was also conducted to 
see if the average length of hospitalization and β2-agonist dose consumed within 24 hours 
significantly varied between the clusters. Further details of the trials are provided below.  
1. First trial, k = 3. The results are presented in Table 12a and 12b.  
2. Second trial, k = 2. The results are presented in Table 13a and 13b.  
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Table 12a. Result for cluster analysis with k = 3 
 
Variable 
Cluster  
F 
 
χ
2 
 
p 1 
n = 43 
2 
n = 94 
3 
n = 93 
Gender Female Male Male  2.37 0.305 
Age (years) 1.03 6.11 5.25 46.29 - <0.001 
Neutrophil level 4.51 7.82 9.83 29.34 - <0.001 
Positive for respiratory-related 
virus infection 
Yes Yes Yes - 9.67 0.008 
Positive for HRV Yes Yes Yes - 10.31 0.006 
Positive for HRV-C No No Yes - 14.23 0.001 
Positive for AdV No No No - 5.01 0.082 
Positive for RSV Yes No No - 97.92 <0.001 
Positive for PIV No No No - 0.83 0.659 
Severity of acute exacerbation -0.25 -0.74 0.88 131.89 - <0.001 
Mother ever smoked Yes No No - 8.06 0.018 
Mother smoking now No No No - 0.45 0.799 
Household member ever 
smoked 
No Yes No - 1.55 0.460 
Household member smoking 
now 
No No No - 0.32 0.852 
Cough No No No - 4.74 0.094 
Wheeze Yes Yes Yes - 24.68 <0.001 
Asthma diagnosis No Yes  Yes - 82.05 <0.001 
Previous hospitalization due to 
asthma 
No Yes Yes - 53.39 <0.001 
Family history of asthma Yes Yes Yes - 2.75 0.253 
Aero-allergy status No Yes Yes - 77.72 <0.001 
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Table 12b. One-way ANOVA result for clustering trial 1, k = 3 
 Cluster n Mean  p 
Length of hospitalization 1 43 50.25  0.065 
 2 93 35.10   
 3 93 44.68   
β2-agonist dose in 24 
hours 
1 23 10.48  0.005 
 2 73 12.47   
 3 83 17.63   
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Table 13a. Result for cluster analysis involving all possible covariates with k = 2 
 
 
Variable 
Cluster  
F 
 
χ
2 
 
p 1 
n = 41 
2 
n = 189 
Gender Male Male - 0.52 0.470 
Age (years) 0.98 5.65 84.05 - <0.001 
Neutrophil level 4.41 8.79 42.97 - <0.001 
Positive for respiratory-related 
virus infection 
Yes Yes - 6.64 0.010 
Positive for HRV No Yes - 11.79 0.001 
Positive for HRV-C No No - 14.16 <0.001 
Positive for AdV No No - 4.95 0.026 
Positive for RSV Yes No - 96.96 <0.001 
Positive for PIV No No - 0.29 0.589 
Severity of acute exacerbation -0.30 0.08 4.76 - 0.030 
Mother ever smoked Yes No - 7.89 0.005 
Mother smoking now No No - 0.01 0.911 
Household member ever smoked Yes No - 0.49 0.483 
Household member smoking now No No - 0.22 0.642 
Cough No No - 2.02 0.155 
Wheeze Yes Yes - 24.72 <0.001 
Asthma diagnosis No Yes - 78.66 <0.001 
Previous hospitalization due to 
asthma 
No Yes - 50.77 <0.001 
Family history of asthma Yes Yes - 3.32 0.069 
Aero-allergy status No Yes - 72.45 <0.001 
 
Table 13b. One-way ANOVA result for clustering trial 1, k = 2 
 Cluster n Mean  p 
Length of hospitalization 1 41 50.45 0.113 
 2 188 39.96   
β2-agonist dose in 24 
hours 
1 21 9.57  0.040 
 2 158 15.27   
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It was found that three groups (k = 3) yielded a better result compared to two groups (k = 2). 
The sample size got imbalanced when k = 2 and thus k = 3 was the one chosen.  
 
The result showed that there were significantly distinct clusters memberships emerging 
within the identified clinical phenotypes and risk factors among the cohort. The main 
characteristics that differentiated the clusters were age, neutrophils level, positive for HRV, 
positive for RSV, wheezing, aero-atopy/allergy, previous hospitalisation due to asthma, 
asthma diagnosis, mother’s current smoking status and family history of asthma. More details 
of the cluster memberships’ main characteristics are provided in Table 14.   
 
Table 14. Main characteristics of the cluster memberships 
Main characteristics Cluster 1 Cluster 2 Cluster 3 
Age (years) [median (IQR)] 1 (0.2 to 1.5) 5.7 (3.1 to 8.8) 4.4 (3.1 to 7.3) 
Neutrophil level (x 109 g/L) 
[median (IQR)] 
3.8 (2.6 to 6.1) 8.3 (5 to 10.4) 9.4 (6.6 to 12.4) 
Severity of acute exacerbation 
(z-score) [median (IQR)] 
0.3 (-0.7 to -0.8) -0.5 (-1 to -0.5) 0.7 (0.3 to 1.2) 
Positive for HRV 51% 73% 77% 
Positive for HRV-C 19% 46% 53% 
Positive for RSV 65% 9% 2% 
Wheezing 63% 95% 87% 
Aero-atopic / allergic 5% 75% 79% 
Has been previously hospitalised 
due to asthma  
2% 69% 54% 
Asthmatic 5% 84% 69% 
Mother currently smokes 23% 19% 23% 
Has a family history of asthma  72% 82% 84% 
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Last part of the cluster analysis process was to conduct a chi-square test to determine how the 
clusters associated with asthma-related genotypes CD14-159CT and CC16-38AG. However, 
the sample size was considered too small and there was no valid case for both genotypes in 
Cluster 1. The analysis was then terminated here and did not proceed any further.  
 
Long-term outcomes 
Summary of study participants’ hospital presentations 
Overall the subset of data had 533 cases observed, however due to missing observations, 
and/or lost hospital notes, the majority of variables had less than 533 cases in them. The 
average number of total number of hospital presentations post-recruitment was around 5 
visits. The average age at first hospital presentation for respiratory purpose was 33 months. 
More details on the study participants’ hospital presentations are provided in Table 15.  
 
Table 15. Summary of study participants’ hospital presentations 
Variable  n median (min max) 
Age at recruitment, months  532 46  (0 to 213) 
Time at risk, months  506 55  (16 to 145) 
Total inpatient respiratory visits after recruitment  520 1  (0 to 17) 
Total ED respiratory visits after recruitment  520 1  (0 to 17) 
Total number of hospital presentation after recruitment  519 2  (0 to 147) 
 
Both univariate and multivariable negative binomial regression analysis were used in this 
study. Univariate Negative Binomial regression analysis was conducted to determine the 
relationship of each potential covariate, including the cluster memberships, with the total 
number of inpatient hospital admissions and total number of ED visits. Any result from 
univariate analysis that was significant at 20% level was included in the multivariable 
analysis.   
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Inpatient admissions 
It was found that eosinophil level (p = 0.005), positive for HRV-C (p = 0.021), positive for 
RSV (p = 0.009), positive for InfV (p = 0.127), positive for aero-atopy/allergy (p = 0.180), 
household member past smoking status (p = 0.153), household member current smoking 
status (p = 0.157), presence of wheeze (p = 0.001), previous hospitalization due to asthma (p 
= 0.008), length of hospitalization during acute exacerbation (p = 0.035), and the amount of 
reliever administered within 24 hours (p = 0.005) during acute exacerbation played a 
significant part in determining the number of total hospital presentation due to respiratory 
illness after recruitment. Each of this analysis was adjusted for age at recruitment to the 
study. The time at risk was set as the length of time the hospital presentation due to 
respiratory illness was observed for each child. The complete results are provided in Table 
16. 
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Table 16. Univariate negative binomial regression analysis result for total number of 
inpatient visits after recruitment due to respiratory illness, adjusting for age at 
recruitment 
Variable [median (min max)]  RR p 95% CI 
Neutrophil level (ln), x 109 g/L 1.08  0.478 0.88 1.33 
Eosinophil level (ln), x 109 g/L 1.15  0.005 1.04 1.28 
Gender (Female) 1.12  0.256 0.92 1.35 
Positive for respiratory-related virus 
infection 
0.91  0.509 0.68 1.21 
Positive for HRV 1.03  0.793 0.81 1.31 
Positive for HRV-C 1.27 0.021 1.04 1.56 
Positive for AdV 0.67  0.334 0.30 1.51 
Positive for RSV 0.59  0.009 0.40 0.88 
Positive for InfV 0.41  0.127 0.13 1.28 
Positive for PIV 0.79  0.502 0.39 1.58 
Positive for Myco 1.68  0.561 0.29 9.60 
Positive for Aero-atopy and allergy  0.86  0.180 0.69 1.07 
Mother ever smoked 1.05  0.618 0.86 1.28 
Mother smoking now 0.94  0.606 0.73 1.20 
Household member ever smoked 0.85  0.153 0.68 1.06 
Household member smoking now 0.85  0.157 0.68 1.06 
Cough  1.10  0.324 0.91 1.34 
Wheeze 1.80  0.001 1.27 2.57 
Previous hospitalization due to asthma 1.34  0.008 1.08 1.66 
Asthmatic 0.94  0.688 0.71 1.25 
Family history of asthma  0.92  0.561 0.70 1.21 
Severity of acute exacerbation 1.02  0.678 0.92 1.13 
Length of hospitalization during acute 
exacerbation 
1.00 0.035 1.00 1.01 
β2-agonist dose within 24 hours of acute 
exacerbation 
1.01 0.139 1.00 1.02 
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Additional analysis was also conducted to examine whether the number of inpatient visits 
varied between clusters. The result showed that, after adjusting for age at recruitment, there 
was no significant different at 20% level in the total number of inpatient hospital 
representations among clusters (Table 17). 
 
Table 17. Univariate negative binomial regression analysis result for total number of 
inpatient visits after recruitment due to respiratory illness, using cluster memberships 
as covariates and adjusting for age at recruitment 
Cluster memberships RR p 95% CI 
Cluster 1 (Reference group) 
Cluster 2 1.23 0.472 0.70 2.16 
Cluster 3 1.15 0.629 0.66 2.00 
 
The result from univariate analysis was used to build the best-fitted model for the purpose of 
multivariable analysis. All covariates that were identified as significant at 20% level at 
univariate level were treated as potential candidates for multivariable analysis. When fitted as 
a multivariable model, some of the covariates failed to keep their significance level and thus 
were removed.  
 
Eosinophil level (p = 0.002), presence of wheeze (p = 0.008), positive for aero-atopy and 
allergy status (p = 0.007) and household-member past smoking status (p = 0.001) were found 
to be highly significant in influencing the recurrence of a patient’s visit as an inpatient in the 
hospital. More detailed results are provided in Table 18.  
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Table 18. Multivariable Negative Binomial regression analysis result for total number 
of inpatient visits after recruitment due to respiratory illness, adjusting for age at 
recruitment (n = 261) 
Variable     RR    p     95% CI 
Eosinophil level (ln), x 109 g/L 1.20  0.002 1.07 1.34 
Positive for aero-atopy and allergy 0.68  0.007 0.52 0.90 
Household member ever smoked 0.66  0.001 0.52 0.84 
Wheeze 1.81 0.008 1.17 2.82 
Previous hospitalization due to asthma 1.37  0.021 1.05 1.78 
 
Those who with an elevated level of eosinophil, wheeze and had been hospitalized before due 
to asthma had between 1.2 to 1.8 times more inpatient visits compared to those with a normal 
level of eosinophil, did not wheeze and never been hospitalized before. Those who were 
aero-atopic and allergic and used to be exposed to secondhand smoking had 0.7 times less 
inpatient visits than the rest.  
 
ED visits 
It was found that eosinophil level (p = 0.107), female (p = 0.122), maternal past smoking 
status (p = 0.003), maternal current smoking status (p = 0.113), household member past 
smoking status (p = 0.002), household member current smoking status (p = 0.069), asthma 
diagnosis status (p = 0.032), and amount of reliever administered within 24 hours during 
acute exacerbation (p < 0.001) played a significant part in determining the number of total 
ED visits due to respiratory illness after recruitment. Each of this analysis was adjusted for 
age at recruitment to the study. The time at risk was set as the length of time the hospital 
presentation due to respiratory illness was observed for each child. The complete results are 
provided in Table 19.  
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Table 19. Univariate Negative Binomial regression analysis result for total number of 
ED visits after recruitment due to respiratory illness, adjusting for age at recruitment 
Variable                   RR     p     95% CI 
Neutrophil level (ln), x 109 g/L 0.89  0.534 0.62 1.28 
Eosinophil level (ln), x 109 g/L 1.16  0.107 0.97 1.40 
Gender (Female) 1.29  0.122 0.93 1.78 
Positive for respiratory-related virus 
infection 
0.91  0.681 0.58 1.43 
Positive for HRV 1.04  0.858 0.71 1.52 
Positive for HRV-C 1.22 0.260 0.87 1.71 
Positive for AdV 1.82  0.317 0.56 5.90 
Positive for RSV 0.80  0.453 0.45 1.43 
Positive for InfV 0.34  0.266 0.05 2.28 
Positive for PIV 1.10  0.861 0.37 3.26 
Positive for Myco 2.87  0.401 0.25 33.70 
Positive for Aero-atopy and allergy  0.86  0.411 0.61 1.23 
Mother ever smoked 0.61  0.003 0.44 0.84 
Mother smoking now 0.71  0.113 0.47 1.08 
Household member ever smoked 0.57  0.002 0.40 0.82 
Household member smoking now 0.71  0.069 0.49 1.03 
Cough  0.98  0.911 0.71 1.35 
Wheeze 1.40  0.229 0.81 2.40 
Previous hospitalization due to asthma 1.02 0.894 0.71 1.47 
Asthmatic 0.61  0.032 0.39 0.96 
Family history of asthma  1.00  0.993 0.64 1.56 
Severity of acute exacerbation 0.93  0.369 0.79 1.09 
Length of hospitalization 1.00 0.912 0.99 1.00 
β2-agonist dose within 24 hours of acute 
exacerbation 
0.95 <0.001 0.93 0.97 
   
Additional analysis was also conducted to examine whether the number of ED visits varied 
between clusters. The result showed that, after adjusting for age at recruitment, there was no 
significant different at 20% level in the total number of ED visits among clusters (Table 20). 
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Table 20. Univariate Negative Binomial regression analysis result for total number of 
ED visits after recruitment due to respiratory illness, using cluster memberships as 
covariates and adjusting for age at recruitment 
Cluster memberships  RR p 95% CI 
Cluster 1 (Reference group) 
Cluster 2 1.22 0.704 0.44 3.36 
Cluster 3 0.93 0.883 0.35 2.48 
 
Similarly to the inpatient visits, the result from univariate analysis was used to build the best-
fitted model for the purpose of multivariable analysis for ED visits. All covariates that were 
identified as significant at 20% level at univariate level were treated as potential candidates 
for multivariable analysis. When fitted as a multivariable model, some of the covariates failed 
to keep their significance level and thus were removed.  
 
Household-member’s smoking past and amount of reliever administered within 24 hours 
following an acute exacerbation were found to be highly significant in influencing the 
recurrence of a patient’s ED visits (p = 0.028 and p < 0.001, respectively). Those who were 
used to be exposed to secondhand smoking and required more amount of β2-agonist had 0.64 
to 0.95 less visit to ED than the rest. More detailed results are provided in Table 21.  
 
Table 21. Multivariable Negative Binomial regression analysis result for total number 
of ED visits after recruitment due to respiratory illness, adjusting for age at recruitment 
(n = 254) 
Variable     RR    p     95% CI 
Household member ever smoked 0.64  0.028 0.43 0.95 
β2-agonist dose within 24 hours of acute 
exacerbation 
0.95 <0.001 0.93 0.98 
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Discussion 
 
Asthma is a multi-faceted clinical syndrome that is characterized by a high degree of 
phenotypes variability and severity as a result of genetic heritability and environmental 
stimuli (Borish & Jeffrey, 2008; Martinez & Vercelli, 2013). This heterogeneity of asthma 
makes the response to asthma medication varies considerably from patient to patient (Borish 
& Jeffrey, 2008). To date, it is unclear why some children respond differently to the same 
treatment. This study was designed to determine whether the lack of response to treatment 
was underpinned by a group of children with a particular acute wheezing phenotype.  
 
The primary hypothesis of this study is that there is a specific group of acute wheezing 
phenotypes that cause children with these phenotypes not to respond well to the prescribed 
asthma treatment and as a result are likely to relapse and re-present to hospital. The results 
presented in the previous section provide support for this hypothesis and their broader 
meaning and context will be discussed in this section.  
 
Response to treatment 
The length of hospital stay and the amount of inhaled β2-agonist within the first 24 hours of 
acute asthma exacerbation were used as indicators of how well a child is responding to 
treatment. The median length of stay for children in this study was 28 hours with the 25% to 
75% of the stay ranged from 16.5 to 52 hours. The median dose of β2-agonist within 24 hours 
of acute exacerbation was 13 emitted doses with the 25% to 75% of the dose ranged from 9 
to 18 emitted doses.  
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Length of hospital stay 
It was found that gender, respiratory syncytial virus, maternal smoking, previous 
hospitalization due to asthma and the severity of acute asthma exacerbation did significantly 
influence the length of hospital stay. In other words, it is expected that females with any of 
these attributes or risk factors would spend longer time in hospital compared to those without 
by taking about 17% longer hours to discharge.  
 
The association between female gender and length of hospital stay could be attributed to the 
differences between genders in processing the treatment and tolerating the disease (Dell et al., 
2001). Dell et al. (2001) used bivariate models to identify the determinants of short hospital 
stay among children who got admitted due to acute asthma exacerbations. They showed, 
consistently with the finding from this study, that younger age, male gender and mild severity 
of disease to have shorter stay in hospital (Median = 18 hours, Range = 6-24 hours) 
compared to children with the opposite attributes (Median = 47 hours, Range = 26-137 
hours). Shanley et al. (2015) conducted multivariable logistic models to identify factors 
associated with hospitalization length of stay due to childhood asthma. They reported similar 
results with children who were older, females, obese and had complex chronic condition did 
have greater odds of a longer hospital stay with an increased odds ratio between 1.1 to 1.3 
times. In contrast, Schatz et al. (2006) in their study of sex-related differences among 
hospitalized asthma patients found that asthma was more prevalent in male children than in 
female children but no gender differences in terms of asthma severity and the response to 
treatment. More research is needed to examine the effect of gender on asthma mechanism 
more closely.  
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In terms of virus infection, in support to the finding from this study, Guibas et al. (2012) and 
Papadopoulos et al. (2011) found that respiratory-related virus such as rhinovirus, respiratory 
syncytial virus, adenovirus and parainfluenza virus, to be associated with asthma and other 
wheezing phenotypes such as bronchiolitis especially in infancy and early childhood. These 
viruses attack the respiratory pathway and impair bronchial functionality which could 
precipitate severe acute exacerbations in young children (Guibas et al., 2012) that in turn 
would lead in turn could lead to a longer hospital stay. It is quite natural for children who had 
more severe exacerbation to spend longer time in hospital as they would have had worse 
airway inflammation that made it more difficult to reverse (Dell et al., 2001; Dougherty & 
Fahy, 2009). Due to the acute and episodic nature of asthma and the difficulty associated with 
a long-term prevention of asthma exacerbation, it is also likely that these children to have had 
hospital admission at least once in the past 12 months due to their susceptibility to acute 
asthma exacerbation (Kenyon et al., 2014).  
 
It is not surprising that maternal smoking was found to be one of the indicators for the length 
of hospital stay. Tobacco smoke is a major asthma exacerbation-inducing factor both as first 
hand smoke in adults and as second hand smoke (SHS) in children (Guibas et al., 2012). UK 
Royal College of Physicians back in 2010 conducted a study to investigate the impact of 
passive smoking in children and found that the risk of children developing asthma doubled 
when they were exposed to passive smoking. Further study of exposure to SHS by Dong et 
al. (2011) found that passive smoking increases the presence of asthma symptoms in children 
younger than 2 years of age.   
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Dose of inhaled β2-agonist within the first 24 hours of acute asthma exacerbation 
It was found that the amount of β2-agonist within the first 24 hours following an acute asthma 
exacerbation was significantly influenced by viral respiratory infection (VRI), aero-atopy 
and/or allergy status, asthma diagnosis status and the severity of acute asthma exacerbation. 
This suggests that children with acute asthma and symptoms of viral respiratory infection, 
who were aero-atopic and/or allergic and suffered a severe exacerbation, responded less 
effectively to β2-agonist and thus required a higher dose.  
 
The association between respiratory viruses and asthma exacerbation has been well 
documented in the literature. Respiratory viruses have the tendency to infect the lower airway 
which increases the airway inflammation and obstructs the airflow (Papadopoulos et al., 
2011; Singh & Busse, 2006).  This infection can both trigger and worsen asthma symptoms.  
 
Rueter et al. (2012) conducted an asthma study to examine the influence of VRI on treatment 
response in acute asthma cohort. Similarly to this study, they found that the response to 
inhaled β2-agonist in children with VRI symptoms within acute asthma cohort depends on 
whether the VRI clinical symptoms present or not; with those with VRI received a 
significantly higher inhaled β2-agonists dose after 6 hours (p = 0.010), 12 hours (p = 0.002), 
and 24 hours (p = 0.005) compared to those without.  
 
Murray et al. (2006) investigated the relationship between virus infection and allergen 
exposure and suggested that a synergistic interaction may exist between allergens and 
viruses. In other words, the combination of exposure to allergens and VRI symptoms would 
likely to trigger asthma exacerbation in children. This supports the finding from this study 
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that those children who were aero-atopic, allergic, asthmatic and with VRI symptoms tend to 
get more severe exacerbation and needing higher dose of inhaled β2-agonist.  
 
The severity of an acute asthma exacerbation affects the children’s ability to respond to the 
inhaled β2-agonists – in particular those administered in the first 24 hours of exacerbation. 
Children who had more severe exacerbation usually had worse airway inflammation that 
made it more difficult to reverse; this usually result in a higher dose of β2-agonists 
administration (Dell et al., 2001; Guibas et al., 2012).  
 
Cluster memberships  
Cluster analysis was performed because it suits the multifaceted and multifactorial nature of 
asthma. It enabled the exploration of the clinical phenotypes of asthma, in particular acute 
asthma, and the risk factors associated with it. There was no a priori assumption regarding the 
cluster memberships and its constructs. A k-means clustering method was chosen as it best 
suited the study’s medium-sized data, and because it is by far the simplest method that works 
by simply partitioning the available observations (n) into k clusters and then grouping them 
into a cluster with the nearest means. In doing so, k-means maximizes the segregation 
between clusters, thereby, maximizing the possibility of highly distinct clusters to emerge 
(Everitt et al., 2011; Haldar et al., 2008). 
 
Few studies had used cluster analysis in the investigation of asthma phenotypes in adults; 
however, this study was the first in applying cluster analysis to identify asthma phenotypes in 
children – in particular within acute asthma cohort. Haldar et al. (2008) was the first to 
explore the application of k-means cluster analysis, to identify distinct phenotyping groups. 
They performed the clustering algorithm in three independent adult asthma populations 
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which comprised of patients with mild-moderate asthma and those with predominantly 
refractory asthma.  They came up with two clusters that were characterized by symptoms 
expression such as early-onset atopic, obesity; and eosinophilic airway inflammation. Moore 
et al. (2009) applied an unsupervised hierarchical cluster analysis to adult population with 
persistent asthma. They came up with five clusters that were characterized by age, gender, 
atopy status, sputum induction (eosinophils and neutrophils), pulmonary function as 
determinant of severity, and medication use (corticosteroids and β-agonists). Schatz et al. 
(2014) applied a post hoc hierarchical clustering method with the Ward minimum variance 
method to children and adults with difficult-to-treat asthma population. They came up with 
five clusters within each age stratum; which were characterized by gender, atopy status, 
nonwhite race, passive smoke exposure and aspirin sensitivity. The results from the 
abovementioned studies as well as the current study demonstrated the possibility of utilizing 
a multivariable mathematical method to classify clinical phenotypes of asthma. 
 
This study performed a cluster analysis in within children with acute asthma population. The 
analysis yielded three distinctive clusters memberships that were characterized by age, 
neutrophils level, positive for VRI, in particular HRV, HRV-C, RSV and adenovirus; the 
severity of acute exacerbation, maternal smoking history, wheezing, asthma diagnosis status, 
previous hospitalization due to asthma and aero-atopy/allergy status.  
 
The children in cluster 1 were of the youngest age category, suffered an exacerbation of a 
medium level of severity, had the lowest neutrophil level and were positive for VRI, in 
particular HRV and RSV, suffered wheezing episodes and were non-atopic. The majority was 
never been hospitalized before and had never been diagnosed with asthma before. This was 
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mostly because this exacerbation was their first exacerbation due to their young age. The 
majority of them had mother who used to smoke and had family history of asthma.   
 
The children in cluster 2 were of the oldest age category. Their neutrophil level was of a 
medium level and the severity of their exacerbation was the least severe level. They were 
mostly tested positive for viral infection especially HRV and most had wheezing episodes. In 
contrast with children in cluster 1, the majority of children in cluster 2 were atopic. As these 
children were older, most of them had previously diagnosed with asthma and been 
hospitalized due to asthma. The majority of them had a family member who used to smoke 
and had family history of asthma. 
 
The children in cluster 3 were of the middle age category. Their neutrophil level was of the 
highest level and their exacerbation was of the most severe level. They were mostly tested 
positive for viral infection especially HRV-C and most had wheezing episodes. Similar to 
cluster 2, the majority of children in cluster 3 were also atopic, had previously diagnosed with 
asthma and been hospitalized due to asthma. In regards to family background, the majority of 
them had family history of asthma and no smoking history of maternal or other household 
member. 
 
The clusters were significantly associated with the amount of reliever required within 24 
hours of exacerbation, with the more severe cluster required higher amount of reliever. There 
was only a marginal difference between the three clusters in terms of the length of hospital 
presentation with the youngest children spent the longest time in the hospital followed by the 
oldest children and then by the children of mid-category age group. The results from the 
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aforementioned studies as well as this current study demonstrated the possibility of utilizing a 
multivariable mathematical method to classify clinical phenotypes of asthma. 
 
Long-term outcome 
Last part of this study was focused on determining whether the asthma phenotypes identified 
earlier via cluster analysis did influence the recurrence of hospital admission and ED visits 
after the children being recruited into the study. Slightly different phenotypes were found to 
play a major role in classifying which group of children that was likely to relapse and re-
present to hospital as ED patients or admitted as inpatients.   
 
Inpatient admissions 
Children who had an elevated eosinophil level increased their risk of relapse and representing 
themselves back to hospital as inpatients by 20%. The risk increased to by about 80% for 
those who had wheezing episodes within the past 12 months, which was almost double the 
risk of those who did not wheeze. Prior hospital admission due to asthma also did 
significantly increase the likelihood of children to have recurring inpatient visits by about 
37%.  However, it was also found that the risk was reduced by about 22% to 24% for 
children who were aero-atopic/allergic and came from a household whose member/s used to 
smoke.  
 
Elevated eosinophil level is a sign of a more serious airway inflammation, which leads to a 
more severe asthma (Louis et al., 2000). Thus a child with more severe asthma has a higher 
chance to relapse and hospital readmission (Chung et al., 2014). Wheezing is usually 
associated with a recurrent airway obstruction that is largely due to respiratory syncytial virus 
infection and can indicate low levels of lung function (Martinez, 2002; Taussig, 2002). 
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Simply put, wheezing is an indicator that viral infection is present and since viral infection is 
a major determinant of severe acute asthma exacerbation, it has an increased risk of hospital 
readmission as shown in this study (Wark et al., 2013). Prior hospital admission is also an 
important marker of whether a child is likely to be readmitted to hospital following an acute 
exacerbation. Several studies have found that previous asthma admission did increase the risk 
of readmission to about 2 to 3 fold (Auger et al., 2015; Chung et al., 2014; Li et al., 2012; 
Kenyon et al., 2014). A Canadian study back in 1996 (Schaubel et al., 1996) even found that 
the probability of hospital readmission increases with the number of previous asthma 
admission. It has been suggested that the reason for this is because previous asthma 
admission is likely to indicate higher asthma severity, poorer standard of asthma in primary 
care and lower access to asthma care, poor knowledge of asthma care, which would 
potentially lead to subsequent asthma admission (Auger et al., 2015; Chung et al., 2014).   
 
The finding that the risk was reduced for children who were aero-atopic/allergic is in contrast 
with the literature. Atopy has been known as an important phenotype that makes one is prone 
to asthma and more susceptible to a more severe and difficult-to-treat asthma (Schatz et al., 
2013). It is also a major risk factor for asthma exacerbation and interacts with viral infection 
that could lead to an increased risk of hospital admission and readmission in particular in 
HRV-C infected subjects (Cox et al., 2013). It is unclear why and how the risk was reduced 
by about 22% to 24% for children who were aero-atopic/allergic and came from a household 
whose member/s used to smoke – especially as tobacco exposure is also been named as an 
indirect trigger of asthma exacerbation (Chung et al., 2014; Schatz et al., 2013). Nevertheless, 
Auger et al. (2015) reported non-significant association between exposure to cigarette smoke 
and rate of hospital readmission. So there might be an important underlying reason that needs 
to be established by future study before any definitive conclusion can be made. It is also 
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possible that parents and caregivers did not report the full extent of secondhand exposure to 
tobacco that their children have had. As most studies rely solely on information provided by 
parents and caregivers, most children are not tested for exposure to secondhand smoke – i.e. 
no measurement on their serum and saliva for cotinine levels are made; so if there is any 
discrepancy between the actual exposure and self-reported ones, it goes undetected and 
eventually leads to a biased result (Chung et al., 2014). 
 
ED visits 
Household member’s smoking history and the dose of β2-agonist received within the first 24 
hours were found to significantly reduce the likelihood of children to have recurring visit to 
ED by 15% and 32% respectively. It is unclear how the fact that children who lived with a 
smoker would have a lower risk of visiting ED due to respiratory illness compared to those 
who never lived with a smoker. There is a possibility that these children had gone straight to 
inpatient instead of visiting ED when they had exacerbation. Alternatively, similar to the 
inpatient visits, there is a possibility of underreporting by parents and caregivers in terms of 
secondhand exposure to tobacco their children have had which might have biased this result.  
 
On the other hand, it does make perfect sense for children who received large dose of β2-
agonist within the first 24 hours after they had an acute exacerbation to have less recurring 
visit to ED as β2-agonist serves to relieve the airway inflammation and improve the 
pulmonary function and hence less likely to relapse (Dell et al., 2001; Guibas et al., 2012; 
Topal et al., 2014).  
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Conclusion 
In conclusion, this study has demonstrated the use of cluster analysis and multivariable 
regression technique to a clinical setting and showed how these techniques offer an 
alternative approach in identifying distinct asthma phenotypic groups by using the disparity 
in the short-term and long-term response to treatment as predictors.  
 
Strength and limitations of the study 
A major strength of this study is that this is the first study that tries to clarify asthma 
phenotype groups in children with severe asthma by using the data from MAVRIC study. The 
fact that MAVRIC study was undertaken at a single center (at Princess Margaret Hospital) 
also ensured the consistency of the clinical practice and medicine administration used in this 
study. Princess Margaret Hospital for Children is the only tertiary children hospital in WA so 
the study is confident that MAVRIC has captured large proportion of children that suffered 
acute asthma exacerbation especially of high severity ones. The large scale of MAVRIC 
allowed a large sample size for this study which provided adequate means for multivariable 
analysis. MAVRIC also collected a vast amount of information on virus, immune system, 
genes and immune cells were collected which enabled this study to apply a considerable 
measure of statistical control of some potential confounders.   
 
A major limitation of this study is this study only focused on the severe asthma cohort. This 
limits the asthma phenotypes involved in the analysis and hence limits the generalization of 
the interpretation of the result as the predominant phenotypes found in this study might not 
necessarily reflect the phenotypes in the wider population.  
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Another limitation of the study was that virus testing was not done for all the children and the 
genes were typed for only a small proportion of children. This had caused some 
inconsistencies with the result and a significant number of missing values.  
 
Future work in this area might benefit from a broader-based study cohort with a more 
comprehensive set of data to cover more asthma phenotypes and risk factors so as to reflect 
the population more accurately.  
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Appendix 1 
Preliminary exploratory data analysis  
1. Checking the distribution of continuous variables of interest.  
Age 
  
 
Neutrophil level 
  
 
Eosinophil level 
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Severity of acute exacerbation (Z-Scored) 
  
 
Hospital length of stay  
  
 
Dose of inhaled β2-agonist within the first 24 hours of acute asthma exacerbation 
  
 
2. Checking the distribution of categorical variables  
The summary of categorical data is provided in Table 6 of the main report.  
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3. Checking the distribution of count variables 
Inpatient admissions 
  
 
ED visits 
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4. Transformation of selected continuous variables 
Age, neutrophil level, eosinophil level, length of hospitalization and the dose of inhaled β2-
agonist within the first 24 hours of acute asthma exacerbation were all (natural) log-
transformed due to them were being highly skewed. The scatterplots illustrating the 
comparisons between the unlogged variables and logged variables are provided below 
(Figure 1a – 3b).  
 
5. Extreme outliers 
Patient #223 had an unusually long stay at the hospital.  
Patient #226 had an unusually high dose of inhaled β2-agonist within the first 24 hours of 
acute asthma exacerbation and quite a length stay at the hospital. 
Patient #484 had a higher than average (of his/her study peers) eosinophils level, but it is still 
within the normal range (0.0 – 6.0).  
ID Age Neutrophils 
level 
Eosinophils 
level 
Hospital LOS (hrs) β2-agonist within 
the first 24 hours  
223 8.51 1.93 1.23 316.05 Missing 
226 8.94 6.83 0 114.38 130 
484 3.24 13.6 3.8 28.67 17 
 
These outliers had been checked and were confirmed as true cases and not a data entry error 
and thus were included in the analysis.   
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Figure 1a. Age vs. Length of hospitalization stay 
 
 
Figure 1b. Age vs. β2-agonist dose within 24 hours 
  
73 
 
 
Figure 2a. Neutrophils level vs. Length of hospitalization stay 
 
 
Figure 2b. Neutrophil level vs. β2-agonist dose within 24 hours 
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Figure 3a. Eosinophil level vs. Length of hospitalization stay 
 
 
Figure 3b. Eosinophil level vs. β2-agonist dose within 24 hours
  
75 
 
Appendix 2 
 
Model checking 
Regression diagnostics of the final model with the length of hospitalization stay as the 
outcome.  
 
1. Normal probability plot  
 
Figure 4. Normal probability plots of the residuals 
 
2. Residuals versus the fitted values  
 
Figure 5. Plot of the residuals versus the fitted values 
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The assumptions of the linear regression models were tested by examining the normal 
probability plots of the residuals (Figure 4) and the plot of the residuals versus the fitted 
values (Figure 5). Both plots showed that there didn’t seem to be major violations of 
normality of the error term in the final model, homoscedasticity of residuals or any 
indications of extreme non-linearity between the predictors and the outcome.  
 
3. Collinearity diagnostics 
Table 22. Collinearity diagnostics 
Variable VIF 
Gender (Female) 1.01 
Positive for RSV 1.08 
Mother smoking now 1.02 
Previous hospitalisation due to asthma 1.08 
Severity of acute exacerbation 1.03 
Mean VIF 1.05 
 
There was no evidence of collinearity between the predictor variables on the evaluation of the 
variance inflation factors (VIF) with each of the predictor variable showed VIF value close to 
one (Table 22).  
 
Based on the above results of the regression diagnostics, it was concluded that the final 
model was an adequate model.  
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Regression diagnostics of the final model with the dose of inhaled β2-agonist within the first 
24 hours of acute asthma exacerbation as the outcome.  
 
1. Normal probability plot 
 
Figure 6. Normal probability plots of the residuals 
 
2. Residuals versus fitted values 
 
Figure 7. Plot of the residuals versus the fitted values 
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The assumptions of the linear regression models were tested by examining the normal 
probability plots of the residuals (Figure 6) and the plot of the residuals versus the fitted 
values (Figure 7). Both plots showed that there didn’t seem to be major violations of 
normality of the error term in the final model, homoscedasticity of residuals or any 
indications of extreme non-linearity between the predictors and the outcome.  
 
3. Collinearity diagnostics 
Table 23. Collinearity diagnostics 
Variable VIF 
Positive for any virus 1.01 
Positive for aero-atopy and allergy 1.08 
Asthmatic 1.01 
Severity of acute exacerbation 1.01 
Mean VIF 1.05 
 
There was no evidence of collinearity between the predictor variables on the evaluation of the 
variance inflation factors (VIF) with each of the predictor variable showed VIF value close to 
one (Table 23).  
 
Based on the above results of the regression diagnostics, it was concluded that the final 
model was an adequate model. 
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Regression diagnostics for Poisson versus Negative Binomial Regression Models 
1. Distribution of long-term outcome 
Variable Mean Standard deviation Variance 
Inpatient admissions 2.172962 2.393531 5.72899 
ED visits 1.284294 2.101198 4.41503 
 
2. Test for over-dispersion 
A null model was run for each long-term outcome and the result is summarized 
below.  
Variable α (95% CI) p 
Inpatient admissions 0.383 (0.300 – 0.489) <0.001 
ED visits 1.646 (1.312 – 2.066) <0.001 
 
The test results showed evidence that both inpatient admissions and ED visits were 
over-dispersed hence their distribution is not Poisson. Furthermore, Poisson 
distribution implies that variance equals to the mean. This assumption does not appear 
to hold in this instance. Thus we opted to use a negative binomial model that is more 
appropriate for over-dispersed count data.  
 
 
